Zhimin X. Wei
Qingdao, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
CTDSPL2 facilitates resistance to paclitaxel in breast cancer cells by suppressing SCYL1 phosphorylation.
Journal: Cell cycle (Georgetown, Tex.)
Published: April 27, 2026
A case report of pulmonary sarcomatoid carcinoma with right tonsillar enlargement as the first diagnosis
Journal: Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
Published: October 10, 2025
Analysis of clinical features of nasal pleomorphic adenoma
Journal: Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
Published: January 22, 2025
Clinical value of [18F]AlF-NOTA-FAPI-04 PET/CT for assessing early-stage liver fibrosis in adult liver transplantation recipients compared with chronic HBV patients.
Journal: Japanese journal of radiology
Published: October 25, 2023
A Retrospective Study on the Clinicopathologic Characteristics and Outcomes of 179 Cases of Synchronous and Metachronous Bilateral Breast Cancer in China.
Journal: Clinical breast cancer
Published: May 07, 2021
SH3BGRL3, transcribed by STAT3, facilitates glioblastoma tumorigenesis by activating STAT3 signaling.
Journal: Biochemical and biophysical research communications
Published: March 25, 2021
SH3GL3 acts as a novel tumor suppressor in glioblastoma tumorigenesis by inhibiting STAT3 signaling.
SH3GL3 acts as a novel tumor suppressor in glioblastoma tumorigenesis by inhibiting STAT3 signaling.
Journal: Biochemical and biophysical research communications
Published: January 03, 2021
SH3BGRL2 functions as a crucial tumor suppressor in glioblastoma tumorigenesis.
Journal: Biochemical and biophysical research communications
Published: December 31, 2020
HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer.
Journal: Pathology, research and practice
Published: July 03, 2020
Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.
Journal: Breast cancer research and treatment
Published: March 05, 2020
Last Updated: 09/26/2026